NeuroSense Therapeutics Ltd. has been granted a Brazilian patent for its PrimeC composition, extending intellectual property protection in Brazil through October 2042 and strengthening its global IP portfolio.
Key takeaways
Brazilian Patent No. BR 112024007727-6 granted for PrimeC composition, providing protection through October 2042.
Patent follows prior grants in the U.S. (12,097,185) and Australia (2022370513), expanding global IP footprint.
PrimeC is a fixed-dose oral therapy combining ciprofloxacin and celecoxib for ALS, Alzheimer's, and other neurodegenerative diseases.
Company is preparing for Phase 3 pivotal trial (PARAGON) in ALS following positive Phase 2b results and FDA clearance.